Progyny Gestione
Gestione criteri di controllo 4/4
Progyny Il CEO è Pete Anevski, nominato in Jan2022, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 1.09M, composta da 45.7% di stipendio e 54.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.18% delle azioni della società, per un valore di $ 2.38M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 7.7 anni.
Informazioni chiave
Pete Anevski
Amministratore delegato
US$1.1m
Compenso totale
| Percentuale dello stipendio del CEO | 45.7% |
| Mandato del CEO | 2.8yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 2.8yrs |
| Durata media del Consiglio di amministrazione | 7.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively
Nov 21
Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Nov 18Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
Oct 21Progyny: Poor Year Raises Concerns For Future (Downgrade)
Oct 15Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
Sep 29Progyny: Downgrading As Uncertainties Increase
Aug 15Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing
Aug 11At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 20Progyny: Recent Stock Decline Provides Buying Opportunity
Jul 12Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall
Jun 23Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Jun 10Progyny: No Change To Long-Term Outlook
Jun 04Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital
May 06When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?
Jan 25Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue
Dec 12Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$57m |
| Jun 30 2024 | n/a | n/a | US$63m |
| Mar 31 2024 | n/a | n/a | US$61m |
| Dec 31 2023 | US$1m | US$500k | US$62m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$49m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$69m | US$500k | US$30m |
| Sep 30 2022 | n/a | n/a | US$42m |
| Jun 30 2022 | n/a | n/a | US$46m |
| Mar 31 2022 | n/a | n/a | US$56m |
| Dec 31 2021 | US$786k | US$425k | US$66m |
| Sep 30 2021 | n/a | n/a | US$90m |
| Jun 30 2021 | n/a | n/a | US$78m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$910k | US$425k | US$46m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$5m | US$375k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | US$1m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$682k | US$325k | -US$6m |
Compensazione vs Mercato: La retribuzione totale di Pete ($USD 1.09M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.50M ).
Compensazione vs guadagni: La retribuzione di Pete è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Pete Anevski (57 yo)
2.8yrs
Mandato
US$1,093,512
Compensazione
Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$513.57k | 0.061% $ 803.2k | |
| CEO & Director | 2.8yrs | US$1.09m | 0.18% $ 2.4m | |
| President | 2.8yrs | US$1.49m | 0.077% $ 1.0m | |
| Chief Financial Officer | 4.2yrs | US$1.40m | 0.052% $ 686.0k | |
| Executive VP | 2yrs | US$546.22k | 0.020% $ 256.8k | |
| Chief Technology Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Marketing Officer | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| Chief Business Development Officer | 2.8yrs | Nessun dato | Nessun dato | |
| Member of the Medical Advisory Board & Chief Medical Officer | 1.6yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Employer Market Strategy | 2.5yrs | Nessun dato | Nessun dato |
2.8yrs
Durata media
57yo
Età media
Gestione esperta: Il team dirigenziale di PGNY è considerato esperto (durata media dell'incarico 2.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$513.57k | 0.061% $ 803.2k | |
| CEO & Director | 2.8yrs | US$1.09m | 0.18% $ 2.4m | |
| Member of the Medical Advisory Board & Chief Medical Officer | no data | Nessun dato | Nessun dato | |
| Independent Director | 7.9yrs | US$567.30k | 0.48% $ 6.3m | |
| Independent Director | 9.7yrs | US$583.35k | 0.014% $ 187.4k | |
| Lead Independent Director | 14.5yrs | US$653.39k | 0.30% $ 4.0m | |
| Independent Director | 5.1yrs | US$518.30k | 0.0073% $ 95.7k | |
| Independent Director | 5.1yrs | US$606.88k | 0.014% $ 187.4k | |
| Member of the Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Medical Advisory Board | no data | Nessun dato | Nessun dato |
7.7yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PGNY sono considerati esperti (durata media dell'incarico 7.7 anni).